Phase 2, Multi-Center, Double-Blind, Randomized, 2-Arm, Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects with Exertional Heat Stroke (EHS)

drug protocol number
EGL-4104-C-1801
drug sponsor
Eagle Pharmaceuticals
drug study
Dantrolene
drug trial site
Mina Al-Shari' Al-Jadid Hospital
drug status
Ongoing
drug phase